Eurand Initiates Rolling NDA For Zentase To Treat Pancreatic Insufficiency
Fewer competitors expected as FDA’s 2008 PEP guidance deadline looms; market worth $300 million to $700 million, firm tells “The Pink Sheet” DAILY.
Fewer competitors expected as FDA’s 2008 PEP guidance deadline looms; market worth $300 million to $700 million, firm tells “The Pink Sheet” DAILY.